Glyphic Biotechnologies Inc Profile last edited on: 11/16/23
CAGE: 94M19
UEI: F57WT7JZDH19
Business Identifier: Next generation protein sequencing 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
169 Madison Avenue Suite 2216
New York, NY 10016
New York, NY 10016
| (925) 477-7334 |
| letschat@glyphic.bio |
| www.glyphic.bio |
Location: Single
Congr. District: 15
County: San Mateo
Congr. District: 15
County: San Mateo
Public Profile
Structured around sequencing proteins, Glyphic Biotechnologies- with facilities in Berkekey CA and New York City is a biotechnology startup structured around intentions to revolutionize the field of proteomics. While DNA can reveal biological insights, proteins can actually enable definition of what yj himan body can/will do. The principals of Glyphic Biotechnologies Inc are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 1 | NIH | $390,584 | |
| Project Title: Single-molecule protein sequencing by detection and identification of N-terminal amino acids | ||||
| 2023 | 1 | NIH | $358,981 | |
| Project Title: Single-molecule protein sequencing by barcoding of N-terminal amino acids | ||||
| 2023 | 1 | NIH | $408,939 | |
| Project Title: Single-molecule sequencing of post-translational protein modifications | ||||
| 2022 | 1 | NIH | $409,295 | |
| Project Title: Single-molecule protein sequencing by iterative isolation and identification of N-terminal amino acids | ||||
Key People / Management
Daniel M Estandian
Joshua Yang
Joshua Yang
Company News
There are no news available.
